About the Authors

Zenjiro Sampei

Roles Investigation, Methodology, Writing – original draft

sampei.zenjiro97@chugai-pharm.co.jp

Affiliation Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan

Kenta Haraya

Roles Investigation

Affiliation Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan

Tatsuhiko Tachibana

Roles Investigation

Affiliation Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan

Taku Fukuzawa

Roles Investigation

Affiliation Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan

Meiri Shida-Kawazoe

Roles Investigation

Affiliation Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan

Siok Wan Gan

Roles Investigation

Affiliation Chugai Pharmabody Research Pte. Ltd., Singapore, Singapore

Yuichiro Shimizu

Roles Resources

Affiliation Chugai Pharmabody Research Pte. Ltd., Singapore, Singapore

Yoshinao Ruike

Roles Resources

Affiliation Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan

Shu Feng

Roles Methodology

Affiliation Chugai Pharmabody Research Pte. Ltd., Singapore, Singapore

Taichi Kuramochi

Roles Methodology

Affiliation Chugai Pharmabody Research Pte. Ltd., Singapore, Singapore

Masaru Muraoka

Roles Investigation

Affiliation Chugai Pharmabody Research Pte. Ltd., Singapore, Singapore

Takehisa Kitazawa

Roles Supervision

Affiliation Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan

Yoshiki Kawabe

Roles Supervision

Affiliation Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan

Tomoyuki Igawa

Roles Supervision

Affiliation Chugai Pharmabody Research Pte. Ltd., Singapore, Singapore

Kunihiro Hattori

Roles Supervision

Affiliation Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan

Junichi Nezu

Roles Project administration, Supervision

Affiliation Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan

Competing Interests

All the authors are employees and/or shareholders of Chugai, which is conducting the clinical study of SKY59. The authors report the filing of the following patents relevant to the investigational drug SKY59. ZS and YR are the inventors of the patents, “Anti-C5 antibodies and methods of use” (WO/2016/098356) and “Anti-C5 antibodies and methods of use” (WO/2017/217524). ZS is the inventor of the patent, “Anti-C5 antibodies and methods of use” (WO/2017/104779). ZS, K. Haraya, and TF are listed as inventors of the patent, “A pharmaceutical composition for use in the treatment or prevention of a C5-related disease and a method for treating or preventing a C5-related disease” (WO/2018/143266). These do not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.